Depression, comorbidities and the TNF-α system

European Psychiatry

Volumn 23, Issue 6, 2008, Pages 421-429

  Himmerich, H ^a,e   Fulda, S ^a   Linseisen, J ^c   Seiler, H ^b   Wolfram, G ^b   Himmerich, S ^b   Gedrich, K ^b   Kloiber, S ^a   Lucae, S ^a   Ising, M ^a   Uhr, M ^a   Holsboer, F ^a   Pollmacher T ^a,d  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d KLINIKUM INGOLSTADT   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

BMI; Cytokines; Depression; TNF receptor; TNF

Indexed keywords

CYTOKINE; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ARTICLE; ATOPIC DERMATITIS; BLOOD SAMPLING; BODY MASS; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPOPROTEINEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH SURVEY; HISTORY; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PEPTIC ULCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SKIN ALLERGY; SMOKING; THYROID DISEASE;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COMORBIDITY; DEPRESSIVE DISORDER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REFERENCE VALUES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 51249096556     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2008.03.013     Document Type: Article

References (66)

1. Angeli A., Minetto M., Dovio A., and Paccotti P. The overtraining syndrome in athletes: a stress-related disorder. J Endocrinol Invest 27 (2004) 603-612
2. Arzt E., Kovalovsky D., Igaz L.M., Costas M., Plazas P., Refojo D., et al. Functional cross-talk among cytokines, T-cell receptor, and glucocorticoid receptor transcriptional activity and action. Ann N Y Acad Sci 917 (2000) 672-677
3. Bailey K.P. Physical symptoms comorbid with depression and the new antidepressant duloxetine. J Psychosoc Nurs Ment Health Serv 41 (2003) 13-18
4. Besedovsky H.O., and del Rey A. The cytokine-HPA axis feed-back circuit. Z Rheumatol 59 Suppl 2 (2000) 26-30
5. Bondy B., Baghai T.C., Zill P., Bottlender R., Jaeger M., Minov C., et al. Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease?. Mol Psychiatry 7 (2002) 1120-1126
6. Bosworth H.B., Bartash R.M., Olsen M.K., and Steffens D.C. The association of psychosocial factors and depression with hypertension among older adults. Int J Geriatr Psychiatry 18 (2003) 1142-1148
7. Brown E.S., Varghese F.P., and McEwen B.S. Association of depression with medical illness: does cortisol play a role?. Biol Psychiatry 55 (2004) 1-9
8. Brustolim D., Ribeiro-dos-Santos R., Kast R.E., Altschuler E.L., and Soares M.B. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol 6 (2006) 903-907
9. Cizza G., Ravn P., Chrousos G.P., and Gold P.W. Depression: a major, unrecognized risk factor for osteoporosis?. Trends Endocrinol Metab 12 (2001) 198-203
10. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., and Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9 (2008) 46-56
11. Eaton W.E., Armenian H., Gallo J., Pratt L., and Ford D.E. Depression and risk of onset of type II diabetes: a prospective population-based study. Diabetes Care 20 (1996) 1097-1102
12. Gold S.M., and Irwin M.R. Depression and immunity: inflammation and depressive symptoms in multiple sclerosis. Neurol Clin 24 (2006) 507-519
13. Gordon W.A., and Hibbard M.R. Poststroke depression: an examination of the literature. Arch Phys Med Rehabil 1997 78 (1997) 658-663
14. Grewen K.M., Girdler S.S., Hinderliter A., and Light K.C. Depressive symptoms are related to higher ambulatory blood pressure in people with a family history of hypertension. Psychosom Med 66 (2004) 9-16
15. Gupta M.A., and Gupta A.K. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 4 (2003) 833-842
16. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kühn M., Schuld A., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33 (1999) 407-418
17. Hauner H., Bender M., Haastert B., and Hube F. Plasma concentrations of soluble TNF-alpha receptors in obese subjects. Int J Obes Relat Metab Disord 22 (1998) 1239-1243
18. Hickie I., Bennett B., Mitchell P., Wilhelm K., and Orlay W. Clinical and subclinical hypothyroidism in patients with chronic and treatment-resistant depression. Aust N Z J Psychiatry 30 (1996) 246-252
19. Himmerich H. Activity of the TNF-α system in patients with brain disorders and during psychopharmacological treatment. Curr Pharm Anal 3 (2007) 1-5
20. Himmerich H., Binder E.B., Künzel H.E., Schuld A., Lucae S., Uhr M., et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry 60 (2006) 882-888
21. Himmerich H., Fulda S., Linseisen J., Wolfram G., Seiler H., Himmerich S., et al. TNF-α, soluble TNF receptor and interleukin-6 plasma levels in the general population. Eur Cytokine Netw 17 (2006) 196-201
22. Himmerich H., Kaufmann C., Schuld A., and Pollmächer T. Elevation of liver enzyme levels during psychopharmacological treatment is associated with weight gain. J Psychiatr Res 39 (2005) 35-42
23. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23 (2000) 477-501
24. Huang H., Patel D.D., and Manton K.G. The immune system in aging: roles of cytokines, T cells and NK cells. Front Biosci 10 (2005) 192-215
25. Irwin M. Effects of sleep and sleep loss on immunity and cytokines. Brain Behav Immun 16 (2002) 503-512
26. Jess P., and Eldrup J. The personality patterns in patients with duodenal ulcer and ulcer-like dyspepsia and their relationship to the course of the diseases. Hvidovre Ulcer Project Group. J Intern Med 235 (1994) 589-594
27. Kabir A.A., Whelton P.K., Khan M.M., Gustat J., and Chen W. Association of symptoms of depression and obesity with hypertension: the Bogalusa Heart Study. Am J Hypertens 19 (2006) 639-645
28. Kahl K.G., Rudolf S., Stoeckelhuber B.M., Dibbelt L., Gehl H.B., Markhof K., et al. Bone mineral density, markers of bone turnover, and cytokines in young women with borderline personality disorder with and without comorbid major depressive disorder. Am J Psychiatry 162 (2005) 168-174
29. Kahl K.G., Greggersen W., Rudolf S., Stoeckelhuber B.M., Bergmann-Koester C.U., Dibbelt L., et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom Med 68 (2006) 669-674
30. Kapcala L.P., Chautard T., and Eskay R.L. The protective role of the hypothalamic-pituitary-adrenal axis against lethality produced by immune, infectious, and inflammatory stress. Ann N Y Acad Sci 771 (1995) 419-437
31. Kraus T., Haack M., Schuld A., Hinze-Selch D., Koethe D., and Pollmächer T. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry 35 (2002) 220-225
32. Kurina L.M., Goldacre M.J., Yeates D., and Gill L.E. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 55 (2001) 716-720
33. Lederbogen F., Gernoth C., Hamann B., Kniest A., Heuser I., and Deuschle M. Circadian blood pressure regulation in hospitalized depressed patients and non-depressed comparison subjects. Blood Press Monit 8 (2003) 71-76
34. Ledochowski M., Murr C., Sperner-Unterweger B., Neurauter G., and Fuchs D. Association between increased serum cholesterol and signs of depressive mood. Clin Chem Lab Med 41 (2003) 821-824
35. Linthorst A.C., and Reul J.M. Inflammation and brain function under basal conditions and during long-term elevation of brain corticotropin-releasing hormone levels. Adv Exp Med Biol 461 (1999) 129-152
36. Lustman P.J., and Clouse R.E. Depression in diabetic patients: the relationship between mood and glycemic control. J Diabetes Complications 19 (2005) 113-122
37. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 461 (1999) 25-46
38. Maes M., Scharpé S., Meltzer H.Y., Bosmans E., Suy E., Calabrese J., et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res 49 (1993) 11-27
39. Malach M., and Imperato P.J. Depression and acute myocardial infarction. Prev Cardiol 7 (2004) 83-90
40. Miller D.B., and O'Callaghan J.P. Depression, cytokines, and glial function. Metabolism 54 (2005) 33-38
41. Moorman A.J., Mozaffarian D., Wilkinson C.W., Lawler R.L., McDonald G.B., Crane B.A., et al. In patients with heart failure elevated soluble TNF-receptor 1 is associated with higher risk of depression. J Card Fail 13 (2007) 738-743
42. Mrazek D.A. Psychiatric symptoms in patients with asthma causality, comorbidity, or shared genetic etiology. Child Adolesc Psychiatr Clin N Am 12 (2003) 459-471
43. Müller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Müller B., et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 11 (2006) 680-684
44. Müller N., and Schwarz M.J. Immunological aspects of depressive disorders. Nervenarzt 78 (2007) 1261-1273
45. Musselman D.L., Betan E., Larsen H., and Phillips L.S. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 54 (2003) 317-329
46. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 158 (2001) 1252-1257
47. O'Brien S.M., Scott L.V., and Dinan T.G. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 19 (2004) 397-403
48. Pasic J., Levy W.C., and Sullivan M.D. Cytokines in depression and heart failure. Psychosom Med 65 (2003) 181-193
49. Pickering M., Cumiskey D., and O'Conner J.J. Actions of TNF-α on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 90 (2005) 663-670
50. Reichenberg A., Kraus T., Haack M., Schuld A., Pollmächer T., and Yirmiya R. Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology 27 (2002) 945-956
51. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58 (2001) 445-452
52. Reul J.M., Labeur M.S., Wiegers G.J., and Linthorst A.C. Altered neuroimmunoendocrine communication during a condition of chronically increased brain corticotropin-releasing hormone drive. Ann N Y Acad Sci 840 (1998) 444-455
53. Rubin R.R., and Peyrot M. Was Willis right? Thoughts on depression as a cause of diabetes. Diabetes Metab Res Rev 18 (2002) 173-175
54. Schiepers O.J., Wichers M.C., and Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 201-217
55. Schöbitz B., Reul J.M., and Holsboer F. The role of the hypothalamic-pituitary-adrenocortical system during inflammatory conditions. Crit Rev Neurobiol 8 (1994) 263-291
56. Silverman M.N., Pearce B.D., Biron C.A., and Miller A.H. Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol 18 (2005) 41-78
57. Thomas A.J., Kalaria R.N., and O'Brien J.T. Depression and vascular disease: what is the relationship?. J Affect Disord 79 (2004) 81-95
58. Tiemeier H., Hofman A., van Tuijl H.R., Kiliaan A.J., Meijer J., and Breteler M.M. Inflammatory proteins and depression in the elderly. Epidemiology 14 (2003) 103-107
59. Tilders F.J., DeRijk R.H., Van Dam A.M., Vincent V.A., Schotanus K., and Persoons J.H. Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: routes and intermediate signals. Psychoneuroendocrinology 9 (1994) 209-232
60. Timonen M., Jokelainen J., Hakko H., Silvennoinen-Kassinen S., Meyer-Rochow V.B., Herva A., et al. Atopy and depression: results from the Northern Finland 1966 Birth Cohort Study. Mol Psychiatry 8 (2003) 738-744
61. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35
62. Wichers M., and Maes M. The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 5 (2002) 375-388
63. Wright R.J., Cohen R.T., and Cohen S. The impact of stress on the development and expression of atopy. Curr Opin Allergy Clin Immunol 5 (2005) 23-29
64. Yirmiya R. Behavioral and psychological effects of immune activation: implications for 'depression due to a general medical condition'. Curr Opin Psychiatry 10 (1997) 470-476
65. Zhu C.B., Blakely R.D., and Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31 (2006) 2121-2131
66. Zimmermann U., Kraus T., Himmerich H., Schuld A., and Pollmächer T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 37 (2003) 193-220